JSCRX
Price
$21.32
Change
+$0.22 (+1.04%)
Updated
Jun 2 closing price
Net Assets
3.5B
WCMNX
Price
$14.98
Change
+$0.18 (+1.22%)
Updated
Jun 2 closing price
Net Assets
52.45M
Interact to see
Advertisement

JSCRX vs WCMNX

Header iconJSCRX vs WCMNX Comparison
Open Charts JSCRX vs WCMNXBanner chart's image
JSCRX vs WCMNX Comparison Chart in %
View a ticker or compare two or three
VS
JSCRX vs. WCMNX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JSCRX is a Buy and WCMNX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JSCRX has more cash in the bank: 3.5B vs. WCMNX (52.4M). JSCRX pays higher dividends than WCMNX: JSCRX (0.10) vs WCMNX (0.00). JSCRX was incepted earlier than WCMNX: JSCRX (22 years) vs WCMNX (7 years). WCMNX (2.04) is less costly to investors than JSCRX (1.56). WCMNX is a more actively managed with annual turnover of: 89.00 vs. JSCRX (62.00). JSCRX has a lower initial minimum investment than WCMNX: JSCRX (0) vs WCMNX (1000). WCMNX annual gain was more profitable for investors over the last year : 25.42 vs. JSCRX (15.61). WCMNX return over 5 years is better than : -1.40 vs. JSCRX (-18.90).
JSCRXWCMNXJSCRX / WCMNX
Total Expense Ratio1.311.24106%
Annual Report Gross Expense Ratio1.562.0476%
Fund Existence22 years7 years-
Gain YTD10.2409.225111%
Front LoadN/AN/A-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets3.5B52.4M6,677%
Annual Yield % from dividends0.100.00-
Returns for 1 year15.6125.4261%
Returns for 3 years30.6131.2198%
Returns for 5 years-18.90-1.401,351%
Returns for 10 years-0.98N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PDSB1.170.03
+2.63%
PDS Biotechnology Corp
NWBI14.160.19
+1.40%
Northwest Bancshares
AFG128.780.51
+0.40%
American Financial Group
TLNCU10.40N/A
N/A
Talon Capital Corp
FULC3.14-3.28
-51.09%
Fulcrum Therapeutics